Gilead Sciences Inc

GILD · Biotechnology · $186.1B
Powering up
GILD
$150.11
▼ −0.52%
09/18 O 150.56 H 153.23 L 149.57 C 150.11 ▼ −0.52%
Vol 16.4M RS 70
RS rating70
Now vs pivot (%)−4.56%
Tightening (ATR ratio)0.88×
Volume dry-up0.88×
Up/down volume, net0.03
From 52-week high5%
forming
Previous breakout trailed out ▲ +9.29% in Jan
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 30.4 weeks and fell 23% from its ceiling at its deepest. The pivot is $157.29, and the stock closed 4.6% below it. Its relative strength rating is 70.

Also on
Peers
Catalyst roadmap
  1. Earningstentativein 41d
    Quarterly earnings
    Oct 29, 2026
  2. EarningstentativeLLY · industryin 41d
    LLY reports
    Oct 29, 2026
Flagged by the market sweep

Nothing flagged for this company on the last market sweep.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Gilead Sciences Inc (GILD) — The Tape